Overview

An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), schizophreniform or schizoaffective disorders (disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations).

Phase:

Phase 4

Details

Lead Sponsor:

Janssen-Cilag Ltd.

Treatments:

Antipsychotic Agents
Risperidone